Showing results (911-920 of 3,376) with videos related to

Sort By:
Pageof 338
The Lancet. Oncology|July 12, 2011
Effect of dignity therapy on distress and end-of-life experience in terminally ill patients: a randomised controlled trialHarvey Max Chochinov, Linda J Kristjanson, William Breitbart, et al.
The Lancet. Oncology|May 17, 2011
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trialHervé Bonnefoi, Martine Piccart, Jan Bogaerts, et al.
The Lancet. Oncology|May 24, 2011
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational studyAnita Villani, Uri Tabori, Joshua Schiffman, et al.
The Lancet. Oncology|May 20, 2011
Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia: longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohortLi-Sheng Chen, Amy Ming-Fang Yen, Sherry Yueh-Hsia Chiu, et al.
The Lancet. Oncology|April 19, 2011
No paradox, no progress: inverse cancer comorbidity in people with other complex diseasesRafael Tabarés-Seisdedos, Nancy Dumont, Anaïs Baudot, et al.
The Lancet. Oncology|May 31, 2011
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic reviewLinda J M Oostendorp, Peep F M Stalmeier, A Rogier T Donders, et al.
The Lancet. Oncology|May 3, 2011
Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort studyMariëlle Kocken, Theo J M Helmerhorst, Johannes Berkhof, et al.
The Lancet. Oncology|October 14, 2011
Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trialThomas Elter, Liana Gercheva-Kyuchukova, Halyna Pylylpenko, et al.
The Lancet. Oncology|October 22, 2011
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective studyJesus Garcia-Donas, Emilio Esteban, Luis Javier Leandro-García, et al.
The Lancet. Oncology|February 28, 2009
Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient dataStefan Michiels, Aurélie Le Maître, Marc Buyse, et al.
Pageof 338